BRD2 and infection: Additionally, among the 17 initial NAT positive samples that were tested by serology, two were positive for anti-SARS-CoV-2 antibodies [one from 2019 NAT(−)/Ab(+) and one from 2020 NAT(+)/Ab(+)], suggesting that the remaining two of the confirmed NAT(+) donors likely had infections early in course of disease, before an antibody response could develop.